Comparison of Canagliflozin, Dapagliflozin and Empagliflozin added to heart failure treatment in decompensated heart failure patients with type 2 diabetes mellitus
Abstract
構成論文 Masaki Nakagaito, Shuji Joho, Ryuichi Ushijima, Makiko Nakamura, Koichiro Kinugawa, Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus, Circulation Reports, 2019, Volume 1, Issue 10, Pages 405-413, Released October 10, 2019, [Advance publication] Released September 27, 2019, Online ISSN 2434-0790, https://doi.org/10.1253/circrep.CR-19-0070
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.